Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

1 May 2016

Abstract excerpt

Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact. In this study, we investigated the impact of mutations on BRCA1 isoform expression and therapeutic response. Cancer cell lines and tumors harboring mutations in exon 11 of BRCA1 express a BRCA1-Δ11q splice...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27197267
DOI: 10.1158/0008-5472.can-16-0186

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and CisplatinPMID 27197267Read ↗

<i>BRCA1</i> secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceSemantic proximity Read ↗

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceSemantic proximity Read ↗

A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.Semantic proximity Read ↗

Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.Semantic proximity Read ↗

Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.Semantic proximity Read ↗

Emerging roles of BRCA1 alternative splicing.Semantic proximity Read ↗

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistanceSemantic proximity Read ↗

Decoding the <i>BRCA2</i> reversion principles underlying PARP inhibitor resistanceSemantic proximity Read ↗

An inducible BRCA1 expression system with <i>in vivo</i> applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistanceSemantic proximity Read ↗

Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants.Semantic proximity Read ↗

m 6 A‐Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung AdenocarcinomaSemantic proximity Read ↗

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.